Finoriq research workspace
Zentalis Pharmaceuticals, Inc. (ZNTL) Institutional Holdings & 13F Ownership
Zentalis Pharmaceuticals, Inc. develops azenosertib, which is in a Phase 3 clinical trial for. Review ZNTL institutional holders, 13F ownership, and position changes on Finoriq.
Company Snapshot
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is based in San Diego, California.
- Company
- Zentalis Pharmaceuticals, Inc. (ZNTL)
- Ticker
- ZNTL
- Market Cap
- $356.6M
- Latest Price
- $5.01
- Industry
- Biotech & Pharma
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.